12.10.2016
Vita 34 AG DE000A0BL849
DGAP-News: Vita 34 Receives Patent for the Preparation of Umbilical Cord Tissue for Cryo-Preservation
DGAP-News: Vita 34 AG / Key word(s): Patent
Vita 34 Receives Patent for the Preparation of Umbilical Cord Tissue for
Cryo-Preservation
12.10.2016 / 07:30
The issuer is solely responsible for the content of this announcement.
---------------------------------------------------------------------------
Vita 34 Receives Patent for the Preparation of Umbilical Cord Tissue for
Cryo-Preservation
Leipzig, October 12, 2016 - The European Patent Office (EPO) intends to
grant a patent for the preparation and cryo-preservation of umbilical cord
tissue and the cells contained therein. The patent covers all of the
process steps from transport to collection of the stem cells. This is a
process for disinfection, for cryo-preservation, and for the isolation of
cells from umbilical cord tissue.
The patent can extend to 38 countries, among them all 28 member states of
the European Union.
Dr. André Gerth, CEO of Vita 34 AG: "The willingness to grant a patent is a
confirmation of the fact that investments in our research and development
are worthwhile. We are on the right path and will continue to pursue our
strategy of product development and strengthening our market leadership."
In 2013 Vita 34 received a permit for the processing, cryo-preservation and
storage of umbilical cord tissue in accordance with Sec. 20c German
Pharmaceutical Act (AMG) as well as for its collection according to Sec.
20b AMG, thus attaining an important step on the way to becoming a
comprehensive provider.
Vita 34 is now the only stem cell bank in Germany that has a permit not
only for the storage of umbilical cord blood, but also umbilical cord
tissue in accordance with Good Manufacturing Practice (PMG) guidelines, a
decisive differentiator for Vita 34. The company has been continuously able
to increase the number of umbilical cord tissue units stored and, thus,
continues to expand its market leadership in its important home market,
Germany.
Vita 34 will also accelerate growth in the future via the introduction of
new products, thus remaining the innovation leader in Europe. The company
was recognized in 2016 as one of the 100 most innovative medium-sized
companies in Germany.
Company Profile
Vita 34 was founded in 1997 as the first private umbilical cord blood bank
in Europe and, as a complete provider, offers collection logistics,
preparation and storage of umbilical cord blood. The basis for its
successful work is an outstanding position in the technological segment of
cryo-preservation. Here, cells and tissue are preserved alive at some
-190ºC for long periods of time, and can be used if needed in the context
of medical treatment. More than 150,000 families are already taking
advantage of this offering and have provided for their children with a stem
cell deposit at Vita 34.
---------------------------------------------------------------------------
12.10.2016 Dissemination of a Corporate News, transmitted by DGAP - a
service of EQS Group AG.
The issuer is solely responsible for the content of this announcement.
The DGAP Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Archive at www.dgap.de
---------------------------------------------------------------------------
Language: English
Company: Vita 34 AG
Deutscher Platz 5a
04103 Leipzig
Germany
Phone: +49(0341)48792-40
Fax: +49(0341)48792-39
E-mail: [email protected]
Internet: www.vita34.de
ISIN: DE000A0BL849
WKN: A0BL84
Listed: Regulated Market in Frankfurt (Prime Standard); Regulated
Unofficial Market in Berlin, Dusseldorf, Hamburg, Munich,
Stuttgart, Tradegate Exchange
End of News DGAP News Service
---------------------------------------------------------------------------
510829 12.10.2016
|
Weitere Ad-hoc und Unternehmensrelevante Mitteilungen zu
Vita 34 AG ISIN: DE000A0BL849 können Sie bei EQS abrufen
Biotechnologie , A0BL84 , V3V , XETR:V3V